Report
Investor Presentation: Q1 2026
Andrew Peller Limited, Canada’s largest publicly traded wine producer, maintains a robust market position through a diversified portfolio of approximately 50 brands ranging from ultra-premium to value segments. The company operates across Canada with a significant asset base exceeding $500 million, encompassing over 600 acres of owned estates and vineyards in Ontario and British Columbia, alongside modern production facilities. With a history spanning 46 years of dividend payments, the organization focuses on sustained long-term value creation through operational efficiency, brand innovation, and the strategic monetization of non-core assets. Financial performance for the first quarter of fiscal year 2026 demonstrates positive momentum, with EBITA reaching $16.1 million, a 25.4% increase compared to the same period in the previous year. This growth was supported by a 400-basis-point expansion in margins, bringing the quarterly margin to 42.4% on $99.2 million in sales. These results follow a strong fiscal year 2025, which saw annual revenue of $389.6 million and a 25% year-over-year increase in EBITA. The company’s strategic priorities include achieving above-category revenue growth, further margin expansion, and reducing debt levels to a target range of 2.5x to 3.0x. The company leverages a national distribution network of over 11,000 points, including liquor boards, hospitality venues, and retail channels. Key growth drivers involve continued investment in premiumization, the expansion of "better-for-you" and craft beverage alcohol categories, and the development of wine-focused economic clusters. By integrating estate winery experiences—such as the highly visited Peller Estates and Trius—with a broad retail presence, the company aims to capitalize on the economic development potential of Canada’s primary wine regions while maintaining a disciplined approach to capital allocation and debt reduction.
Andrew Peller Limited
Report
Q1 2025 Results
Bristol-Myers Squibb’s first-quarter 2025 results demonstrate a strategic transition toward its growth portfolio, which achieved a 16% year-over-year increase in net sales. While total global net sales reached $11.2 billion, representing a 6% decline compared to the previous year, the company’s performance was bolstered by strong demand for key assets such as Opdivo, Breyanzi, and Camzyos. The company continues to navigate the impact of generic competition on legacy products, including Revlimid, Sprycel, and Pomalyst, while simultaneously advancing a robust pipeline of clinical and regulatory milestones. Financial execution remains disciplined, with the company raising its full-year 2025 guidance for both total revenues and non-GAAP earnings per share. The updated revenue outlook of $45.8 billion to $46.8 billion reflects favorable foreign exchange impacts and stronger-than-anticipated performance in the legacy portfolio. Non-GAAP diluted earnings per share are now projected in the range of $6.70 to $7.00. The company maintains a focus on capital allocation, prioritizing debt reduction—having achieved approximately $6 billion in paydowns toward a $10 billion target—while sustaining its commitment to shareholder dividends and share repurchases. Operational highlights for the quarter include the successful U.S. launch of Opdivo Qvantig and continued volume growth for established oncology and immunology treatments. The company is entering a data-rich period through 2027, with multiple pivotal data readouts expected for new molecular entities and life-cycle management programs. By leveraging improved market access and maintaining a strong balance sheet, the organization aims to sustain its long-term growth trajectory despite ongoing macroeconomic and regulatory challenges.
Bristol-Myers Squibb
